A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
Abstract Background High effectiveness of COVID-19 vaccines is essential for the pandemic control. This study systematically reviewed available evidence on effectiveness of ChAdOx1 and BNT162b2 vaccines in the general population, for improved vaccine policies and strategies. Main body of the abstrac...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2021-08-01
|
| Series: | Bulletin of the National Research Centre |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42269-021-00607-w |
| _version_ | 1818681830402949120 |
|---|---|
| author | Chinonyerem O. Iheanacho Uchenna I. H. Eze Emmanuel A. Adida |
| author_facet | Chinonyerem O. Iheanacho Uchenna I. H. Eze Emmanuel A. Adida |
| author_sort | Chinonyerem O. Iheanacho |
| collection | DOAJ |
| description | Abstract Background High effectiveness of COVID-19 vaccines is essential for the pandemic control. This study systematically reviewed available evidence on effectiveness of ChAdOx1 and BNT162b2 vaccines in the general population, for improved vaccine policies and strategies. Main body of the abstract Using several keywords, a search of Scopus, PubMed, Google scholar and Hinari databases was conducted from December 1, 2020 to June 9, 2021. Eligible studies comprising original studies reporting effectiveness of the vaccines, were included following PRISMA guidelines. Individual studies were assessed for quality using National Heart, Lung and Blood Institute quality assessment tool. A total of 1766 titles were retrieved and 11 were included, out of which only 5 were peer-reviewed. Although data availability was limited, studies suggest equivalent effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccine against SARS-CoV-2 infection and COVID-19 related morbidity and mortality. Vaccine effectiveness increased steadily to about 35 days, with an enhanced effectiveness following the second dose. Short conclusion BNT162 and ChAdOx1 vaccines were associated with equivalent and high effectiveness which increased with time and a second dose in the general population. This encourages continued practice of other preventive measures, particularly during the first week of vaccination, and reinforces the need for a second dose. |
| first_indexed | 2024-12-17T10:09:11Z |
| format | Article |
| id | doaj.art-563c9d77247c46dd8ebaafc0c89c1924 |
| institution | Directory Open Access Journal |
| issn | 2522-8307 |
| language | English |
| last_indexed | 2024-12-17T10:09:11Z |
| publishDate | 2021-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Bulletin of the National Research Centre |
| spelling | doaj.art-563c9d77247c46dd8ebaafc0c89c19242022-12-21T21:53:04ZengSpringerOpenBulletin of the National Research Centre2522-83072021-08-0145111010.1186/s42269-021-00607-wA systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general populationChinonyerem O. Iheanacho0Uchenna I. H. Eze1Emmanuel A. Adida2Department of Clinical Pharmacy and Public Health, Faculty of Pharmacy, University of CalabarDepartment of Clinical Pharmacy and Biopharmarcy, Faculty of Pharmacy, Olabisi Onabanjo UniversityDepartment of Clinical Pharmacy and Public Health, Faculty of Pharmacy, University of CalabarAbstract Background High effectiveness of COVID-19 vaccines is essential for the pandemic control. This study systematically reviewed available evidence on effectiveness of ChAdOx1 and BNT162b2 vaccines in the general population, for improved vaccine policies and strategies. Main body of the abstract Using several keywords, a search of Scopus, PubMed, Google scholar and Hinari databases was conducted from December 1, 2020 to June 9, 2021. Eligible studies comprising original studies reporting effectiveness of the vaccines, were included following PRISMA guidelines. Individual studies were assessed for quality using National Heart, Lung and Blood Institute quality assessment tool. A total of 1766 titles were retrieved and 11 were included, out of which only 5 were peer-reviewed. Although data availability was limited, studies suggest equivalent effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccine against SARS-CoV-2 infection and COVID-19 related morbidity and mortality. Vaccine effectiveness increased steadily to about 35 days, with an enhanced effectiveness following the second dose. Short conclusion BNT162 and ChAdOx1 vaccines were associated with equivalent and high effectiveness which increased with time and a second dose in the general population. This encourages continued practice of other preventive measures, particularly during the first week of vaccination, and reinforces the need for a second dose.https://doi.org/10.1186/s42269-021-00607-wCOVID-19SARS-CoV-2ChAdOx1 vaccineBNT162b2 mRNA vaccineEffectivenessAdenovirus vector-based vaccine |
| spellingShingle | Chinonyerem O. Iheanacho Uchenna I. H. Eze Emmanuel A. Adida A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population Bulletin of the National Research Centre COVID-19 SARS-CoV-2 ChAdOx1 vaccine BNT162b2 mRNA vaccine Effectiveness Adenovirus vector-based vaccine |
| title | A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population |
| title_full | A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population |
| title_fullStr | A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population |
| title_full_unstemmed | A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population |
| title_short | A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population |
| title_sort | systematic review of effectiveness of bnt162b2 mrna and chadox1 adenoviral vector covid 19 vaccines in the general population |
| topic | COVID-19 SARS-CoV-2 ChAdOx1 vaccine BNT162b2 mRNA vaccine Effectiveness Adenovirus vector-based vaccine |
| url | https://doi.org/10.1186/s42269-021-00607-w |
| work_keys_str_mv | AT chinonyeremoiheanacho asystematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation AT uchennaiheze asystematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation AT emmanuelaadida asystematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation AT chinonyeremoiheanacho systematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation AT uchennaiheze systematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation AT emmanuelaadida systematicreviewofeffectivenessofbnt162b2mrnaandchadox1adenoviralvectorcovid19vaccinesinthegeneralpopulation |